z-logo
Premium
Systematic review: Accuracy of body mass index in predicting pre‐eclampsia: bivariate meta‐analysis
Author(s) -
Cnossen JS,
Leeflang MMG,
De Haan EEM,
Mol BWJ,
Van Der Post JAM,
Khan KS,
Ter Riet G
Publication year - 2007
Publication title -
bjog: an international journal of obstetrics and gynaecology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.157
H-Index - 164
eISSN - 1471-0528
pISSN - 1470-0328
DOI - 10.1111/j.1471-0528.2007.01483.x
Subject(s) - medicine , meta analysis , body mass index , receiver operating characteristic , eclampsia , interquartile range , bivariate analysis , medline , cochrane library , population , statistics , obstetrics , pregnancy , mathematics , genetics , environmental health , political science , law , biology
Objective  The objective of this study was to determine the accuracy of body mass index (BMI) (pre‐pregnancy or at booking) in predicting pre‐eclampsia and to explore its potential for clinical application. Design  Systematic review and bivariate meta‐analysis. Setting  Medline, Embase, Cochrane Library, MEDION, manual searching of reference lists of review articles and eligible primary articles, and contact with experts. Population  Pregnant women at any level of risk in any healthcare setting. Methods  Reviewers independently selected studies and extracted data on study characteristics, quality, and accuracy. No language restrictions. Main outcome measures  Pooled sensitivities and specificities (95% CI), a summary receiver operating characteristic curve, and corresponding likelihood ratios (LRs). The potential value of BMI was assessed by combining its predictive capacity for different prevalences of pre‐eclampsia and the therapeutic effectiveness (relative risk 0.90) of aspirin. Results  A total of 36 studies, testing 1 699 073 pregnant women (60 584 women with pre‐eclampsia), met the selection criteria. The median incidence of pre‐eclampsia was 3.9% (interquartile range 1.4–6.8). The area under the curve was 0.64 with 93% of heterogeneity explained by threshold differences. Pooled estimates (95% CI) for all studies with a BMI ≥ 25 were 47% (33–61) for sensitivity and 73% (64–83) for specificity; and 21% (12–31) and 92% (89–95) for a BMI ≥ 35. Corresponding LRs (95% CI) were 1.7 (0.3–11.9) for BMI ≥ 25 and 0.73 (0.22–2.45) for BMI < 25, and 2.7 (1.0–7.3) for BMI ≥ 35 and 0.86 (0.68–1.07) for BMI < 35. The number needed to treat with aspirin to prevent one case of pre‐eclampsia ranges from 714 (no testing, low‐risk women) to 37 (BMI ≥ 35, high‐risk women). Conclusions  BMI appears to be a fairly weak predictor for pre‐eclampsia. Although BMI is virtually free of cost, noninvasive, and ubiquitously available, its usefulness as a stand‐alone test for risk stratification must await formal cost‐utility analysis. The findings of this review may serve as input for such analyses.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here